Literature DB >> 27701733

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Natasha Dubois Cauwelaert1, Susan L Baldwin1, Mark T Orr1,2, Anthony L Desbien1,3, Emily Gage1, Kimberly A Hofmeyer1, Rhea N Coler1,2,4.   

Abstract

The contribution of B cells to immunity against many infectious diseases is unquestionably important and well characterized. Here, we sought to determine the role of B cells in the induction of T-helper 1 (TH 1) CD4+ T cells upon vaccination with a tuberculosis (TB) antigen combined with a TLR4 agonist. We used B-cell deficient mice (μMT-/- ), tetramer-positive CD4+ T cells, markers of memory "precursor" effector cells (MPECs), and T-cell adoptive transfers and demonstrated that the early antigen-specific cytokine-producing TH 1 responses are unaffected in the absence of B cells, however MPEC induction is strongly impaired resulting in a deficiency of the memory TH 1 response in μMT-/- mice. We further show that antigen-presentation by B cells is necessary for their role in MPEC generation using B-cell adoptive transfers from wt or MHC class II knock-out mice into μMT-/- mice. Our study challenges the view that B-cell deficiency exclusively alters the TH 1 response at memory time-points. Collectively, our results provide new insights on the multifaceted roles of B cells that will have a high impact on vaccine development against several pathogens including those requiring TH 1 cell-mediated immunity.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  B cells · T cells · μMT−/− mice · memory precursor effector cells · TLR4 agonist

Mesh:

Substances:

Year:  2016        PMID: 27701733      PMCID: PMC5172604          DOI: 10.1002/eji.201646399

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  46 in total

1.  Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.

Authors:  Alison Crawford; Megan Macleod; Ton Schumacher; Louise Corlett; David Gray
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

Review 2.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

3.  CD4+ T cell responses in mice lacking MHC class II molecules specifically on B cells.

Authors:  G S Williams; A Oxenius; H Hengartner; C Benoist; D Mathis
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

4.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

5.  MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Authors:  Mark T Orr; Malcolm S Duthie; Hillarie Plessner Windish; Elyse A Lucas; Jeffrey A Guderian; Thomas E Hudson; Narek Shaverdian; Joanne O'Donnell; Anthony L Desbien; Steven G Reed; Rhea N Coler
Journal:  Eur J Immunol       Date:  2013-07-03       Impact factor: 5.532

Review 6.  Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

Authors:  Stamatis-Nick C Liossis; Petros P Sfikakis
Journal:  Clin Immunol       Date:  2008-03-11       Impact factor: 3.969

7.  Requirement of B cells for generating CD4+ T cell memory.

Authors:  Jason K Whitmire; Mary S Asano; Susan M Kaech; Surojit Sarkar; Lynn G Hannum; Mark J Shlomchik; Rafi Ahmed
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 8.  Hepatitis B virus reactivation with a rituximab-containing regimen.

Authors:  Yutaka Tsutsumi; Yoshiya Yamamoto; Shinichi Ito; Hiroyuki Ohigashi; Souichi Shiratori; Hirohito Naruse; Takanori Teshima
Journal:  World J Hepatol       Date:  2015-09-28

9.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

10.  A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Authors:  Rhea N Coler; Susan L Baldwin; Narek Shaverdian; Sylvie Bertholet; Steven J Reed; Vanitha S Raman; Xiuhua Lu; Joshua DeVos; Kathy Hancock; Jacqueline M Katz; Thomas S Vedvick; Malcolm S Duthie; Christopher H Clegg; Neal Van Hoeven; Steven G Reed
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more
  4 in total

Review 1.  Non-canonical B cell functions in transplantation.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Hum Immunol       Date:  2019-04-10       Impact factor: 2.850

2.  CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.

Authors:  Zhuangwei Lv; Ping Zhang; Dandan Li; Mengting Qin; Longzhu Nie; Xiaoqian Wang; Li Ai; Zhaozu Feng; Woodvine Otieno Odhiambo; Yunfeng Ma; Yanhong Ji
Journal:  Oncoimmunology       Date:  2020-04-21       Impact factor: 8.110

Review 3.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

Review 4.  How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?

Authors:  Robin A Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.